CompletedNot Applicable

Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease

Hong Kong69 participantsStarted 2022-12-09

Plain-language summary

This is a randomized placebo- and active-controlled trial for assessing the efficacy of bright light therapy for sleep and mood symptoms in patients with Parkinson's disease

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Idiopathic Parkinson's disease diagnosed by neurologist according to the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria
✓. Capable to give informed consent
✓. Maintained on stable dose of medications for Parkinson's disease/psychotropic drugs for at least four weeks prior to entry of the study
✓. Score 14 or more on the Epworth Sleepiness Scale

Exclusion criteria

✕. A current or past history of manic or hypomanic episode, schizophrenia, mental retardation, or substance use disorder. (Subjects with depression or anxiety disorders will not be excluded)
✕. Unstable medical or psychiatric condition
✕. Presence of substantial suicidal risk as judged by the clinician and/or screening instruments
✕. Presence of active psychotic symptoms that might impair the ability to consent or validity of the interview
✕. Cognitive impairment with score of 19 or below by the Hong Kong version of Montreal Cognitive Assessment (HK-MoCA)
✕. Contraindication to bright light therapy: history of light induced migraine. Epilepsy, current use of photosensitizing medications, presence of eye disease, e.g. retinal disease, severe cataract, glaucoma and blindness
✕. Significant medical condition/ hearing impairment/ speech deficit lead to incapability in completing clinical interview
✕. Regular shift worker or trans-meridian flight in the past three months

What they're measuring

Change of daytime sleepiness

Timeframe: at the end of 6-week treatment

Trial details

NCT IDNCT05524961

SponsorChinese University of Hong Kong

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-03

View on ClinicalTrials.gov More Parkinson Disease trials